Peptic Ulcer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Peptic Ulcer Market Outlook

Thelansis’s “Peptic Ulcer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Peptic Ulcer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Peptic Ulcer Overview

A peptic gastric or duodenal ulcer is a painful sore or raw area that develops in the stomach lining or intestine. Gastric ulcers are situated within the stomach, while duodenal ulcers are found at the start of the small intestine, known as the duodenum. An individual can simultaneously have both types of ulcers, and some may experience no symptoms. In contrast, others may suffer from belly pain, nausea, vomiting, or a feeling of fullness. The most concerning symptom associated with ulcers is bleeding. The primary culprits behind peptic ulcers are Helicobacter pylori infections and a group of medications called NSAIDs. NSAIDs are widely used because they are available without a prescription, making them a common cause of peptic ulcers. They induce ulcers by disrupting the natural protective mechanisms of the stomach and duodenum against stomach acid and can also affect blood clotting, which is especially significant when ulcers bleed. Diagnosing ulcers typically involves a procedure known as an EGD (EsophagoGastroDuodenoscopy). Treatment for ulcers varies depending on several factors. Nearly all peptic ulcers are managed with proton pump inhibitors (PPIs), potent drugs that block stomach acid production and can be taken orally or administered intravenously. The intravenous form is often used for hospitalized patients with bleeding ulcers. There are six PPIs available in the United States: omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole, and dexlansoprazole, and they share very few medical distinctions.

• In the United States, approximately four million individuals currently suffer from active peptic ulcers, with around 350,000 new cases being diagnosed annually. Duodenal ulcers are four times more common than gastric ulcers.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: